The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Authors
Ghaneh, PKleeff, J
Halloran, C
Raraty, M
Jackson, R
Melling, J
Jones, O
Palmer, D
Cox, T
Smith, C
O'Reilly, D
Izbicki, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Padbury, R
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Rawcliffe, C
Campbell, F
Strobel, O
Büchler, M
Neoptolemos, J
Affiliation
Liverpool Cancer Research U.K. Cancer Trials Unit, University of Liverpool, LiverpoolIssue Date
2017-10-24
Metadata
Show full item recordAbstract
Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies.Citation
The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. 2017, Ann SurgJournal
Annals of SurgeryDOI
10.1097/SLA.0000000000002557PubMed ID
29068800Type
ArticleLanguage
enISSN
1528-1140ae974a485f413a2113503eed53cd6c53
10.1097/SLA.0000000000002557
Scopus Count
Collections
Related articles
- Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
- Authors: Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ting Y, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Lerch MM, Mayerle J, Tjaden C, Strobel O, Hackert T, Büchler MW, Neoptolemos JP, European Study Group for Pancreatic Cancer
- Issue date: 2019 Nov 1
- Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
- Authors: Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW, European Study Group for Pancreatic Cancer
- Issue date: 2001 Dec
- Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
- Authors: Schmocker RK, Delitto D, Wright MJ, Ding D, Cameron JL, Lafaro KJ, Burns WR, Wolfgang CL, Burkhart RA, He J
- Issue date: 2021 Apr
- Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
- Authors: Pine JK, Haugk B, Robinson SM, Darne A, Wilson C, Sen G, French JJ, White SA, Manas DM, Charnley RM
- Issue date: 2020 Apr
- The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
- Authors: Nitta T, Nakamura T, Mitsuhashi T, Asano T, Okamura K, Tsuchikawa T, Tamoto E, Murakami S, Noji T, Kurashima Y, Ebihara Y, Nakanishi Y, Shichinohe T, Hirano S
- Issue date: 2017 Apr